Protalix BioTherapeutics (PLX) Free Cash Flow (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Free Cash Flow of $21.3 million for Q1 2026, up 487.68% year-over-year from $3.6 million in Q1 2025, and up 634.25% quarter-over-quarter from $2.9 million in Q4 2025.
Protalix BioTherapeutics (PLX) Free Cash Flow (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at $21.3 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 487.68% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $14.4 million (up 773.86% YoY), while the FY2025 annual figure was -$12.4 million, down 267.23% from the prior year.
- Free Cash Flow for Q1 2026 stood at $21.3 million, up from $2.9 million in the prior quarter.
- The five-year high for Free Cash Flow was $21.3 million in Q1 2026, with the low at -$9.3 million in Q3 2022.
- The 5-year median for Free Cash Flow is -$3.3 million (2023), against an average of -$634176.5.
- The sharpest annual moves came in 2022 and 2026: Free Cash Flow sank 319.42% in 2022, then jumped 487.68% in 2026.
- Protalix BioTherapeutics' Free Cash Flow stood at -$2.5 million in 2022, then jumped by 252.22% to $3.9 million in 2023, then retreated by 8.09% to $3.6 million in 2024, then retreated by 18.79% to $2.9 million in 2025, then surged by 634.25% to $21.3 million in 2026.
- Business Quant data shows PLX's Free Cash Flow at $21.3 million in Q1 2026, $2.9 million in Q4 2025, and -$4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -10.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.99 Mn |
| Jun 30, 2026 | -10.99 Mn |
| Mar 31, 2026 | 21.26 Mn |
| Mar 31, 2026 | 21.26 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2025 | -4.59 Mn |
| Sep 30, 2025 | -4.59 Mn |
| Jun 30, 2025 | -5.18 Mn |
| Jun 30, 2025 | -5.18 Mn |
| Mar 31, 2025 | -5.49 Mn |
| Mar 31, 2025 | -5.49 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Sep 30, 2024 | 3.37 Mn |
| Sep 30, 2024 | 3.37 Mn |
| Jun 30, 2024 | -3.59 Mn |
| Jun 30, 2024 | -3.59 Mn |
| Mar 31, 2024 | 4.04 Mn |
| Mar 31, 2024 | 4.04 Mn |